For the quarter ended March 2025, Ultragenyx (RARE) reported revenue of $139.29 million, up 28% over the same period last year. EPS came in at -$1.57, compared to -$2.03 in the year-ago quarter.
The reported revenue represents a surprise of -1.90% over the Zacks Consensus Estimate of $141.99 million. With the consensus EPS estimate being -$1.54, the EPS surprise was -1.95%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ultragenyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales- Mepsevii: $8.39 million versus the seven-analyst average estimate of $7.63 million.
- Revenues- Product sales- Dojolvi: $17.01 million versus $21.47 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +4% change.
- Revenues- Product sales- Evkeeza: $11.03 million versus the seven-analyst average estimate of $10.58 million. The reported number represents a year-over-year change of +236.8%.
- Revenues- Product sales: $91.51 million compared to the $75.76 million average estimate based on four analysts. The reported number represents a change of +46.4% year over year.
View all Key Company Metrics for Ultragenyx here>>>
Shares of Ultragenyx have returned +20.9% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
